{"commentary":{"count":17,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":7,"podcast":5,"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07005128\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DeLLphi-312","nct_id":"NCT07005128","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellphi-312-nct07005128. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"DeLLphi-312","arms":[{"description":"Participants will receive tarlatamab in combination with durvalumab, carboplatin and etoposide for 4 cycles followed by tarlatamab and durvalumab.","label":"Tarlatamab + Durvalumab + Carboplatin + Etoposide","type":"EXPERIMENTAL"},{"description":"Participants will receive durvalumab, carboplatin and etoposide for 4 cycles followed by durvalumab.","label":"Durvalumab + Carboplatin + Etoposide","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2029-08-15","type":"ESTIMATED"},"conditions":["Small-cell Lung Cancer","Extensive Stage Small-cell Lung Cancer"],"enrollment":{"count":350,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tarlatamab","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Etoposide","type":"DRUG"}],"last_update":"2026-09-08","lead_sponsor":"Amgen","official_title":"A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-01-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3.5 years"},{"measure":"Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)","timeFrame":"Up to approximately 3.5 years"}],"references":[],"start_date":{"date":"2025-08-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","url":"https://clinicaltrials.gov/study/NCT07005128"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellphi-312-nct07005128"}